查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2020126

避孕药具市场规模、份额、成长及全球产业分析：按类型、应用和地区分類的洞察，2026-2034 年预测

Contraceptive Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 151 Pages | 商品交期: 请询问到货日

价格

避孕药具市场的成长要素

受人们对计划生育和生殖健康意识不断提高的推动，全球避孕药具市场正经历稳定成长。预计到2025年，该市场规模将达到212.1亿美元，2026年将成长至228.1亿美元，到2034年将达到447.4亿美元，预测期内复合年增长率为8.79%。

由于较高的意识层级、有利的报销政策以及大型製药企业的存在，预计到 2025 年，北美将以 38.52% 的市场份额主导全球市场。

市场概览

避孕药具广泛用于预防意外怀孕和管理生殖健康。这些药物，包括口服避孕药、注射和贴剂，在人口控制和预防性性行为感染方面发挥着至关重要的作用。

随着人们对人口快速成长的担忧日益加剧，尤其是在中低收入国家，世界各国政府和医疗机构正在加强避孕宣传。宣传活动和教育计画显着提高了全球避孕普及率。

新冠疫情的影响

新冠疫情对避孕药具市场造成了负面影响，供应链中断和计划生育服务取得受限是主要原因。许多国家的生殖健康服务受到影响。

然而，随着 2020 年至 2021 年间封锁限制的放鬆和计划生育项目的恢復，市场逐渐復苏，全球对避孕药具的需求也随之恢復。

市场趋势

向现代避孕方法过渡

影响市场的主要趋势之一是从传统避孕方式转向口服避孕药、注射和荷尔蒙贴片等现代方法。与传统方法相比，这些现代方法被认为具有更高的有效性和便利性。

现代避孕方法的日益普及，尤其是在职业女性和都市区中，极大地促进了市场成长。

市场驱动因素

公众意识的提高和政府倡议

政府计画、非政府组织和製药公司都在积极推广避孕意识提升。拜耳公司和曼金製药等公司所进行的宣传活动在扩大避孕解决方案的可及性方面发挥了至关重要的作用。

优惠的还款措施

在已开发地区，特别是北美和欧洲，支持性的报销机制发挥了积极作用。保障免费或补贴取得避孕药具的政策显着提高了产品的使用率。

意外怀孕率上升

全球意外怀孕人数的不断增加是推动避孕药需求成长的另一个重要因素，尤其是在新兴经济体。

市场限制因素

儘管预计市场将保持强劲成长，但以下因素可能会限制市场扩张：

  • 副作用包括噁心、头痛和体重增加。
  • 增加长期健康併发症的风险
  • 发展中地区的社会偏见和意识不足
  • 避孕套和子宫内避孕器（IUD）等替代品的可用性

这些因素可能会限制它在某些地区的普及。

細項分析

副产品

口服避孕药目前占据市场主导地位，预计到2026年将占91.39%的市场。其主导地位主要归功于口服避孕药的易用性、可及性和消费者对其的强烈偏好。注射避孕药由于其成本效益，预计也将显着成长。

透过分销管道

预计到2026年，零售药局将占据最大的市场份额，达到45.47%，这主要得益于非处方避孕药供应量的增加。线上管道因其便利性和折扣优惠而迅速崛起。

区域趋势

  • 北美：在高品牌知名度和诱人激励措施的推动下，预计到 2025 年市场规模将达到 81.7 亿美元，到 2026 年将达到 87 亿美元。
  • 欧洲：预计到 2025 年将达到 52.9 亿美元，这得益于其强大的医疗保健基础设施。
  • 亚太地区：预计到 2025 年将达到 42.9 亿美元，这主要得益于政府倡议以及印度和中国等国家日益增强的意识。
  • 拉丁美洲、中东和非洲：由于宣传宣传活动的增加和医疗保健服务的改善，这些地区呈现稳定成长的态势。

主要行业趋势

  • 2023 年：FDA核准了第一款非处方口服避孕药（欧必乐）。
  • 2023年：Lupin公司生产的非专利避孕药已获得FDA核准。
  • 2022年：拜耳获得资金用于非荷尔蒙避孕药的研究。
  • 2022年：Mithra Pharmaceuticals在澳洲推出了「NEXTSTELLIS」。

儘管副作用和社会障碍等挑战依然存在，但持续的产品创新和生殖健康服务可近性的提高有望维持长期成长。未来十年，该市场预计将在全球人口控制和女性健康促进方面发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 2025年总合国家/地区总和生育率
  • 2025年主要国家口服避孕药使用率
  • 主要国家注射避孕药的普及率（2025 年）
  • 管道分析，主要企业
  • 监管趋势－避孕药具，主要地区
  • 重大工业发展－併购、新产品发布
  • 新冠疫情对市场的影响

第五章：2021-2034年全球避孕药具市场分析、洞察与预测

  • 市场分析、洞察与预测：按产品划分。
    • 口服
      • 复方避孕药
      • 仅含黄体素的避孕药
    • 注射药物
    • 修补
  • 市场分析、洞察与预测：按分销管道划分
    • 医院药房
    • 零售药房
    • 诊所
    • 线上管道
    • 公共管道和非政府组织
    • 其他的
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美避孕药具市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲避孕药具市场分析、洞察与预测（2021-2034年）

  • 国家
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太地区避孕药具市场分析、洞察与预测（2021-2034年）

  • 国家
    • 印度
    • 中国
    • 日本
    • 澳洲
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲避孕药具市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲

第十章：中东和非洲避孕药具市场分析、洞察与预测（2021-2034年）

  • 国家
    • GCC
    • 南非
    • 其他中东和非洲国家

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Piramal Enterprises Ltd.
    • Agile Therapeutics
    • Johnson & Johnson Services, Inc.
    • AbbVie Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Amneal Pharmaceuticals LLC
    • Bayer AG
Product Code: FBI100063

Growth Factors of contraceptive drugs Market

The global contraceptive drugs market is experiencing steady growth driven by rising awareness of family planning and reproductive health. The market was valued at USD 21.21 billion in 2025 and is projected to grow to USD 22.81 billion in 2026, reaching USD 44.74 billion by 2034, registering a CAGR of 8.79% during the forecast period.

North America dominated the global market with a 38.52% share in 2025, supported by strong awareness levels, favorable reimbursement policies, and the presence of major pharmaceutical players.

Market Overview

Contraceptive drugs are widely used to prevent unintended pregnancies and manage reproductive health. These drugs, including oral pills, injectables, and patches, play a critical role in population control and reducing the spread of sexually transmitted diseases.

Growing concerns about rapid population growth, especially in low- and middle-income countries, have led governments and healthcare organizations to increase awareness regarding contraception methods. Campaigns and educational initiatives are significantly improving adoption rates worldwide.

Impact of COVID-19

The COVID-19 pandemic negatively impacted the contraceptive drugs market due to supply chain disruptions and reduced access to family planning services. Many countries experienced interruptions in reproductive healthcare services.

However, the market recovered gradually during 2020-2021 as lockdown restrictions eased and family planning programs resumed, restoring demand for contraceptive drugs globally.

Market Trends

Shift Toward Modern Contraceptive Methods

A major trend shaping the market is the transition from traditional to modern contraceptive methods such as oral pills, injectables, and hormonal patches. These methods offer higher effectiveness and convenience compared to conventional options.

The increasing adoption of modern contraception, particularly among working women and urban populations, is significantly boosting market growth.

Market Drivers

Rising Awareness and Government Initiatives

Government programs, NGOs, and pharmaceutical companies are actively promoting contraception awareness. Campaigns such as those by Bayer AG and Mankind Pharma have played a key role in expanding access to contraceptive solutions.

Favorable Reimbursement Policies

Developed regions, particularly North America and Europe, benefit from supportive reimbursement frameworks. Policies ensuring free or subsidized contraceptive access have significantly increased product adoption.

Increasing Unintended Pregnancies

The rising number of unintended pregnancies globally is another critical factor driving demand for contraceptive drugs, especially in emerging economies.

Market Restraints

Despite strong growth, several factors may limit market expansion:

  • Side effects such as nausea, headaches, and weight gain
  • Increased risk of long-term health complications
  • Social stigma and lack of awareness in developing regions
  • Availability of alternative methods such as condoms and intrauterine devices (IUDs)

These factors may restrict widespread adoption in certain regions.

Segmentation Analysis

By Product

The oral contraceptives segment dominated the market, accounting for 91.39% share in 2026. This dominance is due to ease of use, widespread availability, and strong consumer preference. Injectable products are expected to witness significant growth due to their cost-effectiveness.

By Distribution Channel

The retail pharmacy segment held the largest share of 45.47% in 2026, driven by the growing availability of over-the-counter contraceptive drugs. Online channels are emerging rapidly due to convenience and discounts.

Regional Insights

  • North America: Valued at USD 8.17 billion in 2025 and USD 8.70 billion in 2026, driven by high awareness and favorable policies.
  • Europe: Accounted for USD 5.29 billion in 2025, supported by strong healthcare infrastructure.
  • Asia Pacific: Reached USD 4.29 billion in 2025, fueled by government initiatives and rising awareness in countries such as India and China.
  • Latin America & Middle East & Africa: Showing steady growth due to increasing awareness campaigns and improving healthcare access.

Competitive Landscape

The market is fragmented with several global and regional players focusing on innovation and partnerships. Key companies include:

  • Pfizer Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries
  • Viatris Inc.
  • Johnson & Johnson

These companies are investing in product innovation, generic drug development, and strategic collaborations to strengthen their market presence.

Key Industry Developments

  • 2023: FDA approved the first non-prescription oral contraceptive (Opill).
  • 2023: Lupin received FDA approval for generic contraceptive tablets.
  • 2022: Bayer received funding for non-hormonal contraceptive research.
  • 2022: Mithra Pharmaceuticals launched NEXTSTELLIS in Australia.

Conclusion

The contraceptive drugs market is poised for steady expansion, growing from USD 21.21 billion in 2025 to USD 44.74 billion by 2034. Increasing awareness, supportive government initiatives, and the shift toward modern contraceptive methods are key growth drivers.

While challenges such as side effects and social barriers persist, continuous product innovation and improved access to reproductive healthcare will sustain long-term growth. The market is expected to play a vital role in global population control and women's health advancement over the coming decade.

Segmentation

By Product

  • Oral
    • Combined Contraceptives
    • Progestin-only Pills
  • Injectable
  • Patches

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Clinics
  • Online Channels
  • Public Channels & NGOs
  • Others

By Region

  • North America (By Product, By Distribution Channel, and By Country)
    • U.S. (By Product)
    • Canada (By Product)
  • Europe (By Product, By Distribution Channel, and By Country/Sub-region)
    • U.K. (By Product)
    • Germany (By Product)
    • France (By Product)
    • Italy (By Product)
    • Spain (By Product)
    • Scandinavia (By Product)
    • Rest of Europe (By Product)
  • Asia Pacific (By Product, By Distribution Channel, and By Country/Sub-region)
    • Japan (By Product)
    • China (By Product)
    • India (By Product)
    • Australia (By Product)
    • Southeast Asia (By Product)
    • Rest of Asia Pacific (By Product)
  • Latin America (By Product, By Distribution Channel, and By Country/Sub-region)
    • Brazil (By Product)
    • Mexico (By Product)
    • Rest of Latin America (By Product)
  • Middle East & Africa (By Product, By Distribution Channel, and By Country/Sub-region)
    • GCC (By Product)
    • South Africa (By Product)
    • Rest of Middle East & Africa (By Product)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Total Fertility Rate, By Key Countries/ Region, 2025
  • 4.2. Penetration of Oral Contraceptive Pills, Key Countries, 2025
  • 4.3. Penetration of Injectable Contraceptives, Key Countries, 2025
  • 4.4. Pipeline Analysis, Key Players
  • 4.5. Regulatory Scenario - Contraceptive Drugs, Key Regions
  • 4.6. Key Industry Developments- Mergers, Acquisitions, New Product Launches
  • 4.7. Impact of COVID-19 on the Market

5. Global Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Oral
      • 5.1.1.1. Combined Contraceptives
      • 5.1.1.2. Progestin-only Pills
    • 5.1.2. Injectable
    • 5.1.3. Patches
  • 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.2.1. Hospital Pharmacy
    • 5.2.2. Retail Pharmacy
    • 5.2.3. Clinics
    • 5.2.4. Online Channel
    • 5.2.5. Public Channel & NGOs
    • 5.2.6. Others
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Oral
      • 6.1.1.1. Combined Contraceptives
      • 6.1.1.2. Progestin-only Pills
    • 6.1.2. Injectable
    • 6.1.3. Patches
  • 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.2.1. Hospital Pharmacy
    • 6.2.2. Retail Pharmacy
    • 6.2.3. Clinics
    • 6.2.4. Online Channel
    • 6.2.5. Public Channel & NGOs
    • 6.2.6. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
      • 6.3.1.1. By Product
    • 6.3.2. Canada
      • 6.3.2.1. By Product

7. Europe Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Oral
      • 7.1.1.1. Combined Contraceptives
      • 7.1.1.2. Progestin-only Pills
    • 7.1.2. Injectable
    • 7.1.3. Patches
  • 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.2.1. Hospital Pharmacy
    • 7.2.2. Retail Pharmacy
    • 7.2.3. Clinics
    • 7.2.4. Online Channel
    • 7.2.5. Public Channel & NGOs
    • 7.2.6. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.3.1. Germany
      • 7.3.1.1. By Product
    • 7.3.2. U.K.
      • 7.3.2.1. By Product
    • 7.3.3. France
      • 7.3.3.1. By Product
    • 7.3.4. Italy
      • 7.3.4.1. By Product
    • 7.3.5. Spain
      • 7.3.5.1. By Product
    • 7.3.6. Scandinavia
      • 7.3.6.1. By Product
    • 7.3.7. Rest of Europe
      • 7.3.7.1. By Product

8. Asia Pacific Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Oral
      • 8.1.1.1. Combined Contraceptives
      • 8.1.1.2. Progestin-only Pills
    • 8.1.2. Injectable
    • 8.1.3. Patches
  • 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.2.1. Hospital Pharmacy
    • 8.2.2. Retail Pharmacy
    • 8.2.3. Clinics
    • 8.2.4. Online Channel
    • 8.2.5. Public Channel & NGOs
    • 8.2.6. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.3.1. India
      • 8.3.1.1. By Product
    • 8.3.2. China
      • 8.3.2.1. By Product
    • 8.3.3. Japan
      • 8.3.3.1. By Product
    • 8.3.4. Australia
      • 8.3.4.1. By Product
    • 8.3.5. Southeast Asia
      • 8.3.5.1. By Product
    • 8.3.6. Rest of Asia Pacific
      • 8.3.6.1. By Product

9. Latin America Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Oral
      • 9.1.1.1. Combined Contraceptives
      • 9.1.1.2. Progestin-only Pills
    • 9.1.2. Injectable
    • 9.1.3. Patches
  • 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.2.1. Hospital Pharmacy
    • 9.2.2. Retail Pharmacy
    • 9.2.3. Clinics
    • 9.2.4. Online Channel
    • 9.2.5. Public Channel & NGOs
    • 9.2.6. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.3.1. Brazil
      • 9.3.1.1. By Product
    • 9.3.2. Mexico
      • 9.3.2.1. By Product
    • 9.3.3. Rest of Latin America
      • 9.3.3.1. By Product

10. Middle East & Africa Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Oral
      • 10.1.1.1. Combined Contraceptives
      • 10.1.1.2. Progestin-only Pills
    • 10.1.2. Injectable
    • 10.1.3. Patches
  • 10.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.2.1. Hospital Pharmacy
    • 10.2.2. Retail Pharmacy
    • 10.2.3. Clinics
    • 10.2.4. Online Channel
    • 10.2.5. Public Channel & NGOs
    • 10.2.6. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.3.1. GCC
      • 10.3.1.1. By Product
    • 10.3.2. South Africa
      • 10.3.2.1. By Product
    • 10.3.3. Rest of Middle East & Africa
      • 10.3.3.1. By Product

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Piramal Enterprises Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Product
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. Agile Therapeutics
      • 11.2.2.1. Overview
      • 11.2.2.2. Product
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Product
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. AbbVie Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Product
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Pfizer Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Product
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Teva Pharmaceutical Industries Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Product
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Viatris Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Product
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Amneal Pharmaceuticals LLC
      • 11.2.8.1. Overview
      • 11.2.8.2. Product
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. Bayer AG
      • 11.2.9.1. Overview
      • 11.2.9.2. Product
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. financials (Based on Availability)

List of Tables

  • Table 01: Global Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 02: Global Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 03: Global Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 04: Global Contraceptive Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 05: North America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 06: North America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 07: North America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 08: North America Contraceptive Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 09: U.S. Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 10: Canada Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 11: Europe Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 12: Europe Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 13: Europe Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 14: Europe Contraceptive Drugs Market Revenue (USD billion) Forecast, by Country / Sub-region, 2021-2034
  • Table 15: Germany Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 16: U.K. Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 17: France Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 18: Italy Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 19: Spain Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 20: Scandinavia Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 21: Rest of Europe Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 22: Asia Pacific Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 23: Asia Pacific Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 24: Asia Pacific Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Asia Pacific Contraceptive Drugs Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 26: India Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 27: China Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 28: Japan Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 29: Australia Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 30: Southeast Asia Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 31: Rest of Asia Pacific Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 32: Latin America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 33: Latin America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 34: Latin America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 35: Latin America Contraceptive Drugs Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 36: Brazil Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 37: Mexico Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 38: Rest of Latin America Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 39: Middle East & Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 40: Middle East & Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, by Oral Contraceptives, 2021-2034
  • Table 41: Middle East & Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 42: Middle East and Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 43: GCC Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 44: South Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 45: Rest of Middle East and Africa Contraceptive Drugs Market Revenue (USD billion) Forecast, By Product, 2021-2034

List of Figures

  • Figure 01: Global Contraceptive Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 02: Global Contraceptive Drugs Market Revenue Share (%), by Product, 2025 & 2034
  • Figure 03: Global Contraceptive Drugs Market Revenue Share (%), by Distribution Channel, 2025 & 2034
  • Figure 04: Global Contraceptive Drugs Market Revenue Share (%), by Region, 2025 & 2034
  • Figure 05: North America Contraceptive Drugs Market Value (USD billion), by Product, 2025 & 2034
  • Figure 06: North America Contraceptive Drugs Market Revenue Share (%), by Product, 2025
  • Figure 07: North America Contraceptive Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 08: North America Contraceptive Drugs Market Revenue Share (%), by Distribution Channel, 2025
  • Figure 09: North America Contraceptive Drugs Market Value (USD billion), by Country, 2025 & 2034
  • Figure 10: North America Contraceptive Drugs Market Value Share (%), by Country, 2025
  • Figure 11: Europe Contraceptive Drugs Market Value (USD billion), by Product, 2025 & 2034
  • Figure 12: Europe Contraceptive Drugs Market Value Share (%), by Product, 2025
  • Figure 13: Europe Contraceptive Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: Europe Contraceptive Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: Europe Contraceptive Drugs Market Value (USD billion), by Country / Sub-region, 2025 & 2034
  • Figure 16: Europe Contraceptive Drugs Market Value Share (%), by Country / Sub-region, 2025
  • Figure 17: Asia Pacific Contraceptive Drugs Market Value (USD billion), by Product, 2025 & 2034
  • Figure 18: Asia Pacific Contraceptive Drugs Market Revenue Share (%), by Product, 2025
  • Figure 19: Asia Pacific Contraceptive Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: Asia Pacific Contraceptive Drugs Market Revenue Share (%), by Distribution Channel, 2025
  • Figure 21: Asia Pacific Contraceptive Drugs Market Value (USD billion), by Country/Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Contraceptive Drugs Market Revenue Share (%), by Country/Sub-region, 2025
  • Figure 23: Latin America Contraceptive Drugs Market Value (USD billion), by Product, 2025 & 2034
  • Figure 24: Latin America Contraceptive Drugs Market Revenue Share (%), by Product, 2025
  • Figure 25: Latin America Contraceptive Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 26: Latin America Contraceptive Drugs Market Revenue Share (%), by Distribution Channel, 2025
  • Figure 27: Latin America Contraceptive Drugs Market Value (USD billion), by Country/Sub-region, 2025 & 2034
  • Figure 28: Latin America Contraceptive Drugs Market Revenue Share (%), by Country/Sub-region, 2025
  • Figure 29: Middle East and Africa Contraceptive Drugs Market Value (USD billion), by Product, 2025 & 2034
  • Figure 30: Middle East and Africa Contraceptive Drugs Market Revenue Share (%), by Product, 2025
  • Figure 31: Middle East and Africa Contraceptive Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 32: Middle East and Africa Contraceptive Drugs Market Revenue Share (%), by Distribution Channel, 2025
  • Figure 33: Middle East and Africa Contraceptive Drugs Market Value (USD billion), by Country/Sub-region, 2025 & 2034
  • Figure 34: Middle East and Africa Contraceptive Drugs Market Revenue Share (%), by Country/Sub-region, 2025
  • Figure 35: Global Contraceptive Drugs Market Share (%), By Company, 2025